's Chart of the Day - Amedisys
Related Stocks
 AMED - Amedisys Inc

The Barchart Chart of the Day belongs to the home healthcare stock Amedisys(AMED). I found the stock by using Barchart to sort today's Top Stocks to Own list first by the highest Weighted Alpha then I used the Flipchart feature to review the stocks for consistent price appreciation. Since the Trend Spotter signaled a buy on 5/8 the stock gained 53.43%.

Amedisys, Inc. is a leading provider of healthcare in the home with a vision of becoming the premiere solution for patients. From home health to hospice to personal care, Amedisys team members provide quality, clinically-distinctive care to patients every year. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering them to manage a chronic disease, palliative care for those with a terminal illness, or hospice care at the end of life. They work closely with doctors and other healthcare providers to coordinate services, and every patient has an individual plan of care that meets their specific needs.


Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report.

Barchart technical indicators:

  • 100% technical buy signals
  • 148.18+ Weighted Alpha
  • 131.03% gain in the last year
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 11 new highs and up 18.40% in the last month
  • Relative Strength Index 79.98%
  • Technical support level at 104.06
  • Recently traded at 108.00 with a 50 day moving average of 88.16

Fundamental factors:

  • Market Cap 3.61 billion
  • P/E 35.68
  • Revenue expected to grow 6.60% this year and another 6.30% next year
  • Earnings estimated to increase 45.70% this year, an additional 14.60% next year and continue to compound at an annual rate of 20.65% for the next 5 years
  • Wall Street analysts have 2 strong buy, 3 buy and 6 hold recommendations in place on the stock